As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.